Abstract
Immunoglobulins constitute an innovative product group with a wide spectrum of clinical use. Intravenous immunoglobulin (IVIG) solutions containing IgG in a concentration of 95% or more were introduced in the fifties primarily for the treatment of patients with humoral immunodeficiencies. In primary and secondary humoral immunodeficiencies, intravenously administered immunoglobulins replace the natural immunoglobulins and subsequently maintain the natural function of the humoral immune system. In addition, since 1981, there has been a rapid expansion of use in autoimmune diseases, in particular T-cell- and B-cell-mediated chronic neuroinflammatory diseases. The administration of high-dose IVIG is now accepted for various immune-mediated neuropathies, e.g., in the treatment of Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor-neuropathy. Furthermore the National Institutes of Health (NIH) consensus conference in 1990 set up a list of indications for which there was sufficient evidence to justify IVIG application: idiopathic thrombocytopenic purpura, hypogammaglobulinemia in chronic lymphatic leukemia patients, allogenic bone-marrow transplantation, and Kawasaki syndrome. The use of IVIG in the treatment of several inflammatory disorders is a more recent trend. Potential for the clinical use of immunoglobulins has been shown for inflammatory diseases/syndromes such as rheumatoid arthritis, immunovasculitis, dermatomyositis, sepsis, and others.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hures V, Kasatchkine MD, Vassilev T, et al (1997) Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90:4004–4013
Marshall JC (1994) Infection and the host septic response contribute independently to adverse outcome in critical illness: implications for clinical trials of mediator antagonism. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Heidelberg, pp 1–13
Marshall JC (1999) Organ dysfunction as an outcome measure in clinical trias. Eur J Surg Suppl 584:62–67
Lefering R (1999) Biostatistical outcome evaluation using TISS-28. Eur J Surg Suppl 584:56–61
Neugebauer E, Marggraf G, Lefering R (1999) Immunoglobulins in inflammation: Consensus-assisted protocol development and discussion forum of the ATMI trial. Eur J Surg Suppl 584
Kasatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755
Loop FD, Lytle BW, Cosgrove DM, et al (1990) Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 49:179–187
Ottino G, DePaulis R, Pansini S, et al (1987) Major sternal wound infection after open-heart surgery: a multivariate analysis of risk factors in 2579 consecutive operative procedures. Ann Thorac Surg 44:173–179
Scarr MG, Gott VL, Townsend TR (1984) Mediastinal infection after cardiac surgery. Ann Thorac Surg 38:415–423
Marggraf G, Splittgerber FH, Knox M, et al (1999) Mediastinitis after cardiac surgery — epidemiology and current treatment. Eur J Surg 584:12–16
Solomkin JS (1999) Microbiology and antibiotic treatment: discussion forum on a study protocol on adjuvant treatment of mediastinitis with immunoglobulin (Pentaglobin®) after cardiac surgery (ATMI). Eur J Surg Suppl 584:43–44
Neugebauer E (1994) Multicentre trials in sepsis and septic shock — necessary prerequisites elaborated on the trial of supplement immunoglobulin treatment of Pilz et al. Theor Surg 9:60–62
Opal SM (1996) Criticism of clinical trials in sepsis and organ dysfunction. In: Gullo A (ed) Sepsis and Organ Failure, Vol 4. APICE, Trieste, pp 29–41
Sibbald WI, Vincent IL (1995) Round table conference on clinical trials for the treatment of sepsis. Intensive Care Med 21:184–189
Lorenz W, Neugebauer E, Pilz G, et al (1994) Methodology of clinical trials in sepsis-introduction. Theor Surg 9:10–11
Schein M, Assalia A (1994) The role of planned reoperations and laparotomy in severe intraabdominal infection: is a prospective randomized tdgagadgarial possible? Theor Surg 9:38–42
Troidl H, McKneally MF, Mulder DS, et al (1997) Surgical Research. Basic Principles and Clinical Practice, 3rd edn. Springer, New York
Neugebauer E, Troidl H (1995) Consensus methods as tools to assess medical technologies. Surg Endosc 9:481–482 (Abst)
Neugebauer E, Troidl H, Kum CK, et al (1995) The E.A.E.S. Consensus Development Conferences on laparoscopic cholecystectomy, appendectomy, and hernia repair. Consensus statements. Surg Endosc 9:550–563
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Neugebauer, E., Marggraf, G., Lefering, R. (2002). Adjuvant Treatment of Mediastinitis with Immunoglobulins after Cardiac Surgery: The ATMI Trial. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 2002. Yearbook of Intensive Care and Emergency Medicine 2002, vol 2002. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56011-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-56011-8_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-43149-7
Online ISBN: 978-3-642-56011-8
eBook Packages: Springer Book Archive